Anna L V Johansson1, Therese M-L Andersson2, Anna Plym2, Gustav J Ullenhag3, Henrik Møller4, Mats Lambe5. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: anna.johansson@ki.se. 2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 3. Department of Radiology, Oncology, and Radiation Science, Section of Oncology, Uppsala University, Uppsala, Sweden. 4. Cancer Epidemiology and Population Health, King's College London, London, United Kingdom. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Regional Cancer Center, Uppsala, Sweden.
Abstract
BACKGROUND: Malignant melanoma (MM) is one of the most common malignancies in young women. It remains debated whether a MM diagnosed during pregnancy or lactation has a worse prognosis. OBJECTIVE: We sought to examine mortality in women with pregnancy-associated MM (PAMM) (diagnosed during pregnancy and up to 2-years postpartum). METHODS: This was a population-based cohort study based on information retrieved from the Swedish Cancer and Multi-Generation Registers. Hazard ratios with 95% confidence intervals adjusted for age, period, education, parity, and tumor location were estimated. RESULTS: In total, 6857 women and girls aged 15 to 44 years with a diagnosis of cutaneous MM between 1963 and 2009 were identified. Of these, 1019 cases were classified as PAMM. The cause-specific mortality did not differ between PAMM and MM not diagnosed near childbirth (adjusted hazard ratio 1.09, 95% confidence interval 0.83-1.42). LIMITATIONS: Information on stage at diagnosis was available only for a subset of patients CONCLUSION: Overall, the cause-specific mortality in women and girls with PAMM did not differ from that in women and girls with non-PAMM. The current findings do not provide evidence of an adverse prognostic influence of pregnancy or a recent birth.
BACKGROUND:Malignant melanoma (MM) is one of the most common malignancies in young women. It remains debated whether a MM diagnosed during pregnancy or lactation has a worse prognosis. OBJECTIVE: We sought to examine mortality in women with pregnancy-associated MM (PAMM) (diagnosed during pregnancy and up to 2-years postpartum). METHODS: This was a population-based cohort study based on information retrieved from the Swedish Cancer and Multi-Generation Registers. Hazard ratios with 95% confidence intervals adjusted for age, period, education, parity, and tumor location were estimated. RESULTS: In total, 6857 women and girls aged 15 to 44 years with a diagnosis of cutaneous MM between 1963 and 2009 were identified. Of these, 1019 cases were classified as PAMM. The cause-specific mortality did not differ between PAMM and MM not diagnosed near childbirth (adjusted hazard ratio 1.09, 95% confidence interval 0.83-1.42). LIMITATIONS: Information on stage at diagnosis was available only for a subset of patients CONCLUSION: Overall, the cause-specific mortality in women and girls with PAMM did not differ from that in women and girls with non-PAMM. The current findings do not provide evidence of an adverse prognostic influence of pregnancy or a recent birth.
Authors: M Kiuru; Q Li; G Zhu; J R Terrell; K Beroukhim; E Maverakis; T H M Keegan Journal: J Eur Acad Dermatol Venereol Date: 2022-08-23 Impact factor: 9.228
Authors: Dimitrios C Ziogas; Panagiotis Diamantopoulos; Olga Benopoulou; Amalia Anastasopoulou; Dimitrios Bafaloukos; Alexander J Stratigos; John M Kirkwood; Helen Gogas Journal: Oncologist Date: 2020-04-09